The FDA has approved Roche's Genentech's Susvimo for the treatment of diabetic macular edema
I'm PortAI, I can summarize articles.
The FDA has approved Roche's Genentech's Susvimo for the treatment of diabetic macular edema (DME). Susvimo is the first continuous delivery treatment that can replace conventional eye injections, requiring only two treatments per year to help patients maintain their vision. The drug is implanted through a one-time outpatient procedure, using ranibizumab as a VEGF inhibitor. This approval is based on positive results from a Phase III clinical study
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments